lamotrigine has been researched along with Abnormalities, Congenital in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Callers who contacted the Israeli Teratology Information Service regarding lamotrigine treatment or NTE during pregnancy between 1997 and 2008 were prospectively followed-up." | 7.85 | Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. ( Diav-Citrin, O; Finkel-Pekarsky, V; Ornoy, A; Shechtman, S; Zvi, N, 2017) |
| "Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter." | 7.76 | Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| "In 1992, the International Lamotrigine Pregnancy Registry was initiated to enroll prospectively and to monitor pregnancies exposed to lamotrigine (LTG) for the occurrence of major birth defects." | 7.71 | Preliminary results on pregnancy outcomes in women using lamotrigine. ( Eldridge, RR; Tennis, P, 2002) |
| "Callers who contacted the Israeli Teratology Information Service regarding lamotrigine treatment or NTE during pregnancy between 1997 and 2008 were prospectively followed-up." | 3.85 | Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. ( Diav-Citrin, O; Finkel-Pekarsky, V; Ornoy, A; Shechtman, S; Zvi, N, 2017) |
| "Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter." | 3.76 | Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| "Data from the International Lamotrigine Pregnancy Registry were analyzed to examine the effect of maximal first-trimester maternal dose of lamotrigine monotherapy on the risk of major birth defects (MBDs)." | 3.74 | Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. ( Cunnington, M; Ferber, S; Quartey, G, 2007) |
| "In 1992, the International Lamotrigine Pregnancy Registry was initiated to enroll prospectively and to monitor pregnancies exposed to lamotrigine (LTG) for the occurrence of major birth defects." | 3.71 | Preliminary results on pregnancy outcomes in women using lamotrigine. ( Eldridge, RR; Tennis, P, 2002) |
| "Seizures and intracranial hemorrhage are possible medical diseases that any obstetrician may encounter." | 2.49 | Seizures and intracranial hemorrhage. ( Alexander, JM; Wilson, KL, 2013) |
| "Juvenile myoclonic epilepsy is a common idiopathic generalized epileptic syndrome that includes generalized myoclonic seizures and commonly generalized tonic-clonic and generalized absence seizures." | 2.45 | The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? ( Abou-Khalil, B; Montouris, G, 2009) |
| "The incidence of birth defects in relation to specific AEDs was: valproate (16." | 1.32 | The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. ( Graham, J; Hitchcock, A; Lander, C; O'Brien, TJ; Vajda, FJ, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diav-Citrin, O | 1 |
| Shechtman, S | 1 |
| Zvi, N | 1 |
| Finkel-Pekarsky, V | 1 |
| Ornoy, A | 1 |
| Galappatthy, P | 1 |
| Liyanage, CK | 1 |
| Lucas, MN | 1 |
| Jayasekara, DTLM | 1 |
| Abhayaratna, SA | 1 |
| Weeraratne, C | 1 |
| De Abrew, K | 1 |
| Gunaratne, PS | 1 |
| Gamage, R | 1 |
| Wijeyaratne, CN | 1 |
| Wilson, KL | 1 |
| Alexander, JM | 1 |
| Dolk, H | 1 |
| Jentink, J | 1 |
| Loane, M | 1 |
| Morris, J | 1 |
| de Jong-van den Berg, LT | 1 |
| Montouris, G | 1 |
| Abou-Khalil, B | 1 |
| Vajda, FJ | 2 |
| Graham, JE | 1 |
| Hitchcock, AA | 1 |
| O'Brien, TJ | 2 |
| Lander, CM | 1 |
| Eadie, MJ | 1 |
| Tennis, P | 1 |
| Eldridge, RR | 1 |
| Hitchcock, A | 1 |
| Graham, J | 1 |
| Lander, C | 1 |
| Cunnington, M | 1 |
| Ferber, S | 1 |
| Quartey, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lamotrigine Pregnancy Registry (LAM05)[NCT01064297] | 3,416 participants (Actual) | Observational | 2001-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy with valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 14 |
| First Exposure During Second Trimester | 1 |
| First Exposure During Third Trimester | 0 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 1 |
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy without valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 12 |
| First Exposure During Second Trimester | 0 |
| First Exposure During Third Trimester | 1 |
| All Trimesters | 13 |
Among lamotrigine monotherapy exposures: live births, fetal deaths, induced abortions with birth defects, and live births without defects. Due to the likelihood of inconsistent identification of birth defects among spontaneous losses, fetal deaths, and induced abortions without reported birth defects, these offspring were not included in analyses. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 35 |
| First Exposure During Second Trimester | 4 |
| First Exposure During Third Trimester | 1 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 40 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine monotherapy. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of major congenital malformations are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 31 | 1 | 3 | 1523 | 10 | 33 | 98 |
| First Exposure During Second Trimester | 4 | 0 | 0 | 91 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 17 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy with valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 14 | 0 | 2 | 134 | 1 | 4 | 6 |
| First Exposure During Second Trimester | 1 | 0 | 0 | 6 | 1 | 0 | 0 |
| First Exposure During Third Trimester | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The number of live births, fetal deaths with pregnancy loss occurring >=20 weeks gestation, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy without valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. Although birth defects may not have been reported, they cannot be ruled out. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 11 | 0 | 1 | 418 | 3 | 19 | 22 |
| First Exposure During Second Trimester | 0 | 0 | 0 | 25 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy with valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hydrocephalus/spina bifida | Meningomyelocele | Microcephaly | Orofacial clefts | Cardiac septal defects | Transposition of great vessels | Ventricular hypoplasia | Pulmonary stenosis | Pyloric stenosis | Gastroschisis | Club foot | Polydactyly | |
| Doses Lower Than Prescribed | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Prescribed Doses | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy without valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neural tube defect | Cardiac septal defect/murmur | Coarctation of aorta | Tetralogy of Fallot | Esophageal defects | Hypospadias | Hydroencephalopathy | Omphalocele | Extra digit | Skin tags on ear | |
| Doses Higher Than Prescribed | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| Doses Lower Than Prescribed | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Prescribed Doses | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
The number of infants with the reported MCM following first trimester lamotrigine monotherapy exposure were counted. Registry personnel contacted the enrolling physician to obtain information on the pregnancy outcome, lamotrigine dosing and duration of exposure, and use of concomitant antiepileptic drugs during pregnancy. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anencephaly | Orofacial clefts | Hypoplastic left heart/left ventricle hypoplasia | Transposition of great vessels | Ventricular septal defects | Minor heart defect, unspecified | Pulmonary stenosis | Hydronephrosis | Renal defect (absent, polysystic, fluid on kidney) | Cortical dysplasis | Hypospadias | Pyloric stenosis | Diaphragmatic hernia | Congenital atresia of anus | Hip dislocation | Club feet | Polydactyly | Epidermolysis bullosa | Light spot across entire abdomen | |
| Dose Higher Than Prescribed | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Doses Lower Than Prescribed | 2 | 2 | 1 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
| Prescribed Doses | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| Unknown Maximal Dose in Exposed Trimester | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
2 reviews available for lamotrigine and Abnormalities, Congenital
| Article | Year |
|---|---|
Seizures and intracranial hemorrhage.
Topics: Anticonvulsants; Carbamazepine; Congenital Abnormalities; Eclampsia; Epilepsy; Female; Folic Acid; H | 2013 |
The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
Topics: Anticonvulsants; Congenital Abnormalities; Delayed-Action Preparations; Drug Design; Epilepsy, Gener | 2009 |
7 other studies available for lamotrigine and Abnormalities, Congenital
| Article | Year |
|---|---|
Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Congenital Abnormalities; Female; Humans; Lamotrigine; | 2017 |
Obstetric outcomes and effects on babies born to women treated for epilepsy during pregnancy in a resource limited setting: a comparative cohort study.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anticonvulsants; Body Height; Body Weight; Carbamazepine; | 2018 |
Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?
Topics: Adolescent; Antimanic Agents; Case-Control Studies; Child; Child, Preschool; Cleft Lip; Community He | 2008 |
Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Congenital Abnormalities; Dose-Response Rel | 2010 |
Preliminary results on pregnancy outcomes in women using lamotrigine.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Congenital Abnormalities; Drug Therapy, Combination; E | 2002 |
The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months.
Topics: Abortion, Induced; Anticonvulsants; Australia; Carbamazepine; Cohort Studies; Congenital Abnormaliti | 2003 |
Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Congenital Abnormalities; Databases as Topic; Dose-Res | 2007 |